Spontaneous Tumor Regression in Tasmanian Devils Associated with RASL11A Activation. Issue 4 (1st August 2020)

• Record Type: Journal Article
• Authors: Margres, Mark J; Ruiz-Aravena, Manuel; Hamede, Rodrigo; Chawla, Kusum; Patton, Austin H; Lawrance, Matthew F; Fraik, Alexandra K; Stahlke, Amanda R; Davis, Brian W; Ostrander, Elaine A; Jones, Menna E; McCallum, Hamish; Paddison, Patrick J; Hohenlohe, Paul A; Hockenbery, David; Storfer, Andrew
• Is Part Of: Genetics. Volume 215:Issue 4(2020)
• Page Start: 1143
• Page End: 1152
• Publication Date: 2020-08-01
• Subjects: cancer -- tumor regression -- gene expression -- tumor suppressor; Genetics -- Periodicals; 576.5
• DOI: 10.1534/genetics.120.303428
• Languages: English
• ISSNs: 0016-6731

Abstract

Abstract: Spontaneous cancer regression in humans is uncommon, but understanding the mechanisms is key for advancing treatment. Using Devil Facial Tumor Disease as a model, Margres et al. employed comparative.... Abstract: Spontaneous tumor regression has been documented in a small proportion of human cancer patients, but the specific mechanisms underlying tumor regression without treatment are not well understood. Tasmanian devils are threatened with extinction from a transmissible cancer due to universal susceptibility and a near 100% case fatality rate. In over 10, 000 cases, <20 instances of natural tumor regression have been detected. Previous work in this system has focused on Tasmanian devil genetic variation associated with the regression phenotype. Here, we used comparative and functional genomics to identify tumor genetic variation associated with tumor regression. We show that a single point mutation in the 5′ untranslated region of the putative tumor suppressor RASL11A significantly contributes to tumor regression. RASL11A was expressed in regressed tumors but silenced in wild-type, nonregressed tumors, consistent with RASL11A downregulation in human cancers. Induced RASL11A expression significantly reduced tumor cell proliferation in vitro . The RAS pathway is frequently altered in human cancers, and RASL11A activation may provide a therapeutic treatment option for Tasmanian devils as well as a general mechanism for tumor inhibition.